Regeneron Pharmaceuticals Retained Earnings (Accumulated Deficit) 2010-2024 | REGN

Regeneron Pharmaceuticals retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $30.755B, a 17.83% increase year-over-year.

  • Regeneron Pharmaceuticals retained earnings (accumulated deficit) for 2023 were $27.26B, a 16.96% increase from 2022.
  • Regeneron Pharmaceuticals retained earnings (accumulated deficit) for 2022 were $23.307B, a 22.87% increase from 2021.
  • Regeneron Pharmaceuticals retained earnings (accumulated deficit) for 2021 were $18.968B, a 74.13% increase from 2020.

Regeneron Pharmaceuticals Retained Earnings (Accumulated Deficit) 2010-2024 | REGN

  • Regeneron Pharmaceuticals retained earnings (accumulated deficit) for 2023 were $27.26B, a 16.96% increase from 2022.
  • Regeneron Pharmaceuticals retained earnings (accumulated deficit) for 2022 were $23.307B, a 22.87% increase from 2021.
  • Regeneron Pharmaceuticals retained earnings (accumulated deficit) for 2021 were $18.968B, a 74.13% increase from 2020.